AMD (NYSE:AMD) does not need a merger or buyout as some have written. Those days are long gone. If it were going to happen, it would have been two years prior when AMD was really feeling the pain and the balance sheet was a wreck. Since then they have drastically reduced debt while expanding product offerings. In this article we are going to cover a brief history, growth prospects, why a buyout will not happen, and how Intel (NASDAQ:INTC) might get in bed with AMD.
To look at AMD we have to look to the future. Back in the late 90s and early 2000s AMD was basically a company that specialized in flash memory and had a struggling x86 CPU business. Sure AMD had periods where they were the leader but these were brief due to Intel’s relentless foundry upgrade cycle. AMD could not match Intel from an investment standpoint in the foundries due to cash constraints and product slippage. Nor did Intel’s questionable business practices help but that is for another time. Fast forward to the present. We have an AMD that is emerging from a long healing process and the future outlook is what drives stock prices.
Top 5 Clean Energy Stocks To Invest In 2018: L Brands, Inc.(LB)
- [By Jeremy Bowman]
J.C. Penney and Nordstrom should report holiday sales in the coming days, but there’s evidence elsewhere that it was a weak season for bricks-and-mortar retailers. Shares of Victoria’s Secret parentL Brands(NYSE: LB) were down 9% after it said comparable sales fell 1% in December and that it expects fourth-quarter earnings to come in at the low end of its previously stated guidance of $1.85-$2.00.
- [By Teresa Rivas]
L Brands (LB) ended at the bottom of the S&P 500 on Thursday, after disappointing guidance overshadowed better-than-expected earnings.
L Brands slid $9.19, or 15.8%, to $48.94, its lowest close since 2013. By contrast, the S&P 500 gained 0.99 points, or 0.04%, today to 2363.81.
Oppenheimers Anna Andreeva and Samantha Lanman reiterated an Outperform rating and $75 price target on the stock, but admit that the magnitude of L Brands downward forecast was disappointing, even with weak industry trends signaled by peers like Wal-Mart (WMT), Macys (M), and TJX Cos. (TJX).
While they still are bullish, they admit that the bottom isnt clear:
In the last 5 years, LB’s multiple averaged in high-teens given quality of brands/management, with 13-14x trough not seen since early ’13valuation could still compress assuming guidance isn’t conservative enough. Sticking with Outperform for now, albeit near-term visibility is worsening.
L Brands is down 25% this year.
- [By Paul Ausick]
L Brands Inc. (NYSE: LB) also dropped about 2.6% on Friday to record a new 52-week low of $56.01. The stock closed at $57.48 on Thursday. Volume was about 33% above the daily average of around 2.5 million shares. Wednesday’s report that ecommerce giant Amazon.com is considering competing with the company’s Victoria’s Secret stores has caused some investors to seek greener pastures.
Top 5 Clean Energy Stocks To Invest In 2018: One Horizon Group, Inc.(OHGI)
- [By Lisa Levin] Gainers
Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
Top 5 Clean Energy Stocks To Invest In 2018: BP Prudhoe Bay Royalty Trust(BPT)
- [By WWW.MONEYSHOW.COM]
Our featured recommendation, the BP Prudhoe Bay Royalty Trust (BPT), is a grantor trust. What that means is that the trust holds royalty interest in minerals from the Prudhoe Bay on the North Slope of Alaska.
- [By Lisa Levin]
In trading on Friday, energy shares fell by 1.30 percent. Meanwhile, top losers in the sector included BP Prudhoe Bay Royalty Trust (NYSE: BPT), down 14 percent, and Gulf Island Fabrication, Inc. (NASDAQ: GIFI), down 13 percent.
Top 5 Clean Energy Stocks To Invest In 2018: Mayne Pharma Group Limited (MAYNF)
- [By SEEKINGALPHA.COM]
We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ